• Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845852.
  • Bouaboula M, Desnoyer N, Carayon P, Combes T, Casellas P (1999). Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55: 473480.
  • Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155163.
  • Carrier EJ, Auchampach JA, Hillard CJ (2006). Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Nat Acad Sci USA 103: 78957900.
  • Cheng YC, Prusoff WH (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 30993108.
  • Corbett AD, Henderson G, McKnight AT, Paterson SJ (2006). 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147: S153S162.
  • ElSohly MA, Slade D (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78: 539548.
  • Kathmann M, Flau K, Redmer A, Trankle C, Schlicker E (2006). Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Arch Pharmacol 372: 354361.
  • Leff P (1995). The two-state model of receptor activation. Trends Pharmacol Sci 16: 8997.
  • Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316: 780788.
  • Mignat C, Wille U, Ziegler A (1995). Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci 56: 793799.
  • Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635664.
  • Pertwee RG (2004). The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo, V. (eds) Cannabinoids. Kluwer Academic/Plenum Publishers: New York, pp 3283.
  • Pertwee RG (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76: 13071324.
  • Pertwee RG, Griffin G, Lainton JAH, Huffman JW (1995). Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Eur J Pharmacol 284: 241247.
  • Pertwee RG, Ross RA, Craib SJ, Thomas A (2002). Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99106.
  • Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R (2005). Evidence that (−)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens. Neuropharmacology 48: 11391146.
  • Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta-9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1PL6.
  • Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B et al. (1999). SR144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther 288: 582589.
  • Rhee MH, Kim SK (2002). SR144528 as inverse agonist of CB2 cannabinoid receptor. J Vet Sci 3: 179184.
  • Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126: 665672.
  • Savinainen JR, Saario SM, Niemi R, Jarvinen T, Laitinen JT (2003). An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140: 14511459.
  • Showalter VM, Compton DR, Martin BR, Abood ME (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989999.
  • Thomas A, Baillie GL, Phillips AM, Ross RA, Pertwee RG (2006). Cannabidiol is an inverse agonist and exhibits unexpectedly high potency as an antagonist at mouse brain CB1 and human CB2 receptors. Symposium on the Cannabinoids. Burlington, Vermont, International Cannabinoid Research Society, p 8.
  • Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee RG (2004). 6′-azidohex-2′-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol 487: 213221.
  • Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA et al. (2005). Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917926.
  • Thomas B, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285292.